Document is current

Article History

Accepted: 31 December 2024

First Online: 24 January 2025

Declarations

:

: Prof. Mavrakanas is supported from a Fonds de Recherche Santé Quebec (FRSQ) J1 Clinician Scholar award and a Kidney Research Scientist Core Education and National Training (KRESCENT) program New Investigator Award.

: Celine Konecki, Mark L. Lipman, and Zoubir Djerada have no conflicts of interest that are directly relevant to the content of this article. Prof. Mavrakanas has received speaker honoraria from Bayer, BMS Canada, Janssen, Astra Zeneca, and Pfizer, and has served on advisory boards for Boehringer Ingelheim, Bayer, GSK, and Servier outside the submitted work. He has also received research grants from Astra Zeneca and Pfizer.

: The original study was performed in line with the principles of the Declaration of Helsinki and approval was granted by the Research Ethics Committee of the Jewish General Hospital.

: Participants provided written informed consent.

: Not applicable.

: The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.

: Not applicable.

: CK: conceptualisation, methodology, data curation, formal analysis, investigation, visualisation, writing (original draft). MLL: conceptualisation, methodology, data curation, investigation, resources, writing (review and editing). TAM: conceptualisation, methodology, data curation, investigation, resources, supervision, writing (review and editing). ZD: conceptualisation, methodology, data curation, formal analysis, investigation, supervision, writing (review and editing).